Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate

US12383491B2 · kind B2 · utility

Assignee

• AZURITY PHARMACEUTICALS, INC. · US

Inventors

• Rahul Dhulaji Bhise · Hyderabad, IN
• Ajay Singh · Princeton, US
• Mahadeo Vasant Mahadik · Hyderabad, IN
• Ashish Anilrao Dubewar · Hyderabad, IN
• Molugu Prashanth Reddy · Hyderabad, IN

Key dates

• Filing date: Jul 27, 2021
• Grant date: Aug 12, 2025
• Expiry date: Feb 2, 2044

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K47/183
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Stable, ready-to-use injectable pharmaceutical compositions are provided, comprising the combination of neostigmine, glycopyrrolate, and a pharmaceutically acceptable liquid vehicle, optionally with additional pharmaceutically acceptable excipients. Other aspects of the invention relate to methods for making such compositions and methods of using such compositions for reversing the effects of non-depolarizing neuromuscular blocking agents. Preferably, the composition comprises neostigmine methylsulfate, glycopyrronium bromide, and a pharmaceutically acceptable liquid vehicle, and is provided in a pre-filled, ready-to-use sealed container, such as a pre-filled syringe, suitable for intravenous administration.